Loss of GPR3 reduces the amyloid plaque burden and improves memory in Alzheimer's disease mouse models

Science Translational Medicine

Volumn 7, Issue 309, 2015, Pages

  Huang, Yunhong ^a,b   Skwarek Maruszewska, Aneta ^a,b   Horré, Katrien ^a,b   Vandewyer, Elke ^a,b   Wolfs, Leen ^a,b   Snellinx, An ^a,b   Saito, Takashi ^c,d   Radaelli, Enrico ^a,b   Corthout, Nikky ^a,b   Colombelli, Julien ^e   Lo, Adrian C ^b   Van Aerschot, Leen ^b   Callaerts Vegh, Zsuzsanna ^b   Trabzuni, Daniah ^f,g   Bossers, Koen ^h   Verhaagen, Joost ^h   Ryten, Mina ^f   Munck, Sebastian ^a,b   D'Hooge, Rudi ^b   Swaab, Dick F ^h   Hardy, John ^f   Saido, Takaomi C ^c   De Strooper, Bart ^a,b   Thathiah, Amantha ^a,b   more..

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^e INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^h NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 3; UNCLASSIFIED DRUG; GPR3 PROTEIN, HUMAN;

ADULT; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE DELETION; GPR3 GENE; HUMAN; HUMAN TISSUE; MEMORY; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; ANIMAL; BRAIN; DEFICIENCY; GENE EXPRESSION; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; ANIMALS; BRAIN; GENE DELETION; GENE EXPRESSION; HUMANS; MICE; MICE, TRANSGENIC; MODELS, ANIMAL; PLAQUE, AMYLOID; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84945319051     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.aab3492     Document Type: Article

References (56)

1. E. K. Karran, J. Hardy, A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann. Neurol. 76, 185-205 (2014).
2. B. De Strooper, Lessons from a failed g-secretase Alzheimer trial. Cell 159, 721-726 (2014).
3. W. K. Kroeze, D. J. Sheffler, B. L. Roth, G-protein-coupled receptors at a glance. J. Cell Sci. 116, 4867-4869 (2003).
4. P. Ma, R. Zemmel, Value of novelty? Nat. Rev. Drug Discov. 1, 571-572 (2002).
5. A. Thathiah, K. Spittaels, M. Hoffmann, M. Staes, A. Cohen, K. Horré, M. Vanbrabant, F. Coun, V. Baekelandt, A. Delacourte, D. F. Fischer, D. Pollet, B. De Strooper, P. Merchiers, The orphan G protein-coupled receptor 3 modulates amyloid-beta peptide generation in neurons. Science 323, 946-951 (2009).
6. A. Thathiah, K. Horré, A. Snellinx, E. Vandewyer, Y. Huang, M. Ciesielska, G. De Kloe, S. Munck, B. De Strooper, b-Arrestin 2 regulates Ab generation and g-secretase activity in Alzheimer's disease. Nat. Med. 19, 43-49 (2013).
7. R. Radde, T. Bolmont, S. A. Kaeser, J. Coomaraswamy, D. Lindau, L. Stoltze,M. E. Calhoun, F. Jäggi, H. Wolburg, S. Gengler, C. Haass, B. Ghetti, C. Czech, C. Hölscher, P. M. Mathews, M. Jucker, Aβ42-driven cerebral amyloidosis in transgenicmice reveals early and robust pathology. EMBO Rep. 7, 940-946 (2006).
8. G. A. Elder, M. A. Gama Sosa, R. De Gasperi, Transgenic mouse models of Alzheimer's disease. Mt. Sinai J. Med. 77, 69-81 (2010).
9. E. Levy, M. D. Carman, I. J. Fernandez-Madrid, M. D. Power, I. Lieberburg, S. G. van Duinen, G. T. Bots, W. Luyendijk, B. Frangione, Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type. Science 248, 1124-1126 (1990).
10. A. Lüthi, H. van der Putten, F. M. Botteri, I. M. Mansuy, M.Meins, U. Frey,G. Sansig, C. Portet,M. Schmutz, M. Schröder, C. Nitsch, J.-P. Laurent,D.Monard, Endogenous serine protease inhibitormodulates epileptic activity and hippocampal long-term potentiation. J. Neurosci. 17, 4688-4699 (1997).
11. M. C. Herzig, D. T. Winkler, P. Burgermeister, M. Pfeifer, E. Kohler, S. D. Schmidt, S. Danner, D.Abramowski, C. Stürchler-Pierrat, K. Bürki, S. G. vanDuinen,M. L. C.Maat-Schieman,M. Staufenbiel, P.M. Mathews, M. Jucker, Ab is targeted to the vasculature in amousemodel of hereditary cerebral hemorrhage with amyloidosis. Nat. Neurosci. 7, 954-960 (2004).
12. T. Saito, Y. Matsuba, N. Mihira, J. Takano, P. Nilsson, S. Itohara, N. Iwata, T. C. Saido, Single App knock-in mouse models of Alzheimer's disease. Nat. Neurosci. 17, 661-663 (2014).
13. L. Serneels, J. Van Biervliet, K. Craessaerts, T. Dejaegere, K. Horré, T. Van Houtvin, H. Esselmann, S. Paul, M. K. Schäfer, O. Berezovska, B. T. Hyman, B. Sprangers, R. Sciot, L. Moons, M. Jucker, Z. Yang, P. C.May, E. Karran, J.Wiltfang, R. D'Hooge, B. De Strooper, g-Secretase heterogeneity in the Aph1 subunit: Relevance for Alzheimer's disease. Science 324, 639-642 (2009).
14. O. Valverde, E. Célérier, M. Baranyi, P. Vanderhaeghen, R. Maldonado, B. Sperlagh, G. Vassart, C. Ledent, GPR3 receptor, a novel actor in the emotional-like responses. PLOS One 4, e4704 (2009).
15. K. Andersen, L. J. Launer, M. E. Dewey, L. Letenneur, A. Ott, J. R. Copeland, J. F. Dartigues, P. Kragh-Sorensen, M. Baldereschi, C. Brayne, A. Lobo, J. M. Martinez-Lage, T. Stijnen, A. Hofman; EURODEM Incidence Research Group, Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. Neurology 53, 1992-1997 (1999).
16. L. Fratiglioni, L. J. Launer, K. Andersen, M. M. Breteler, J. R. Copeland, J. F. Dartigues, A. Lobo, J. Martinez-Lage, H. Soininen, A. Hofman, Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54, S10-S15 (2000).
17. L. Fratiglioni, M. Viitanen, E. von Strauss, V. Tontodonati, A. Herlitz, B. Winblad, Very old women at highest risk of dementia and Alzheimer's disease: Incidence data from the Kungsholmen Project, Stockholm. Neurology 48, 132-138 (1997).
18. L. X. Hy, D.M. Keller, Prevalence of AD amongwhites: A summary by levels of severity. Neurology 55, 198-204 (2000).
19. A. F. Jorm, A. E. Korten, A. S. Henderson, The prevalence of dementia: A quantitative integration of the literature. Acta Psychiatr. Scand. 76, 465-479 (1987).
20. P. K. Mölsä, R. J. Marttila, U. K. Rinne, Epidemiology of dementia in a Finnish population. Acta Neurol. Scand. 65, 541-552 (1982).
21. M. J. Callahan,W. J. Lipinski, F. Bian, R. A.Durham, A. Pack, L. C.Walker, Augmented senile plaque load in aged female β-amyloid precursor protein-transgenic mice. Am. J. Pathol. 158, 1173-1177 (2001).
22. C. Hirata-Fukae, H.-F. Li, H.-S. Hoe, A. J. Gray, S. S. Minami, K. Hamada, T. Niikura, F. Hua, H. Tsukagoshi-Nagai, Y. Horikoshi-Sakuraba, M.Mughal, G. W. Rebeck, F.M. LaFerla, M. P. Mattson, N. Iwata, T. C. Saido, W. L. Klein, K. E. Duff, P. S. Aisen, Y.Matsuoka, Females exhibitmore extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res. 1216, 92-103 (2008).
23. D. R. Howlett, J. C. Richardson, A. Austin, A. A. Parsons, S. T. Bate, D. C. Davies, M. I. Gonzalez, Cognitive correlates of Aβ deposition in male and female mice bearing amyloid precursor protein and presenilin-1 mutant transgenes. Brain Res. 1017, 130-136 (2004).
24. L. Placanica, L. Zhu, Y.-M. Li, Gender- and age-dependent γ-secretase activity in mouse brain and its implication in sporadic Alzheimer disease. PLOS One 4, e5088 (2009).
25. S. Schäfer, O. Wirths, G. Multhaup, T. A. Bayer, Gender dependent APP processing in a transgenic mouse model of Alzheimer's disease. J. Neural Transm. 114, 387-394 (2007).
26. J. Wang, H. Tanila, J. Puolivali, I. Kadish, T. van Groen, Gender differences in the amount and deposition of amyloidβ in APPswe and PS1 double transgenic mice. Neurobiol. Dis. 14, 318-327 (2003).
27. R. H. Pietrzak, Y. Y. Lim, A. Neumeister, D. Ames, K. A. Ellis, K. Harrington, N. T. Lautenschlager, C. Restrepo, R. N. Martins, C. L. Masters, V. L. Villemagne, C. C. Rowe, P. Maruff; Australian Imaging, Biomarkers, and Lifestyle Research Group, Amyloid-β, anxiety, and cognitive decline in preclinical Alzheimer disease: A multicenter, prospective cohort study. JAMA Psychiatry 72, 284-291 (2015).
28. L. Prut, C. Belzung, The open field as a paradigm to measure the effects of drugs on anxietylike behaviors: A review. Eur. J. Pharmacol. 463, 3-33 (2003).
29. A. A. Walf, C. A. Frye, The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat. Protoc. 2, 322-328 (2007).
30. R. C. Agis-Balboa, Z. Pavelka, C. Kerimoglu, A. Fischer, Loss of HDAC5 impairs memory function: Implications for Alzheimer's disease. J. Alzheimers Dis. 33, 35-44 (2013).
31. K. Chung, K. Deisseroth, CLARITY formapping the nervous system. Nat. Methods 10, 508-513 (2013).
32. K.Chung, J.Wallace, S.-Y.Kim,S.Kalyanasundaram, A. S. Andalman,T. J.Davidson, J. J.Mirzabekov, K. A. Zalocusky, J.Mattis, A. K. Denisin, S. Pak, H. Bernstein, C. Ramakrishnan, L.Grosenick, V. Gradinaru, K. Deisseroth, Structural and molecular interrogation of intact biological systems. Nature 497, 332-337 (2013).
33. K. Ando,Q. Laborde, A. Lazar, D. Godefroy, I. Youssef,M. Amar, A. Pooler, M.-C. Potier, B. Delatour, C. Duyckaerts, Inside Alzheimer brain with CLARITY: Senile plaques, neurofibrillary tangles and axons in 3-D. Acta Neuropathol. 128, 457-459 (2014).
34. S. M. DeWire, J. D. Violin, Biased ligands for better cardiovascular drugs: Dissecting G-proteincoupled receptor pharmacology. Circ. Res. 109, 205-216 (2011).
35. J. D. Violin, R. J. Lefkowitz, β-Arrestin-biased ligands at seven-transmembrane receptors. Trends Pharmacol. Sci. 28, 416-422 (2007).
36. S. Tanaka, K. Ishii, K. Kasai, S. O. Yoon, Y. Saeki, Neural expression of G protein-coupled receptors GPR3, GPR6, and GPR12 up-regulates cyclic AMP levels and promotes neurite outgrowth. J. Biol. Chem. 282, 10506-10515 (2007).
37. S. Tanaka, I. M. Shaikh, E. A. Chiocca, Y. Saeki, The Gs-linked receptor GPR3 inhibits the proliferation of cerebellar granule cells during postnatal development. PLOS One 4, e5922 (2009).
38. J. Ruiz-Medina, C. Ledent, O. Valverde, GPR3 orphan receptor is involved in neuropathic pain after peripheral nerve injury and regulates morphine-induced antinociception. Neuropharmacology 61, 43-50 (2011).
39. C. Tourino, E. Valjent, J. Ruiz-Medina, D. Herve, C. Ledent, O. Valverde, The orphan receptor GPR3 modulates the early phases of cocaine reinforcement. Br. J. Pharmacol. 167, 892-904 (2012).
40. C. Ledent, I. Demeestere, D. Blum, J. Petermans, T. Hämäläinen, G. Smits, G. Vassart, Premature ovarian aging in mice deficient for Gpr3. Proc. Natl. Acad. Sci. U.S.A. 102, 8922-8926 (2005).
41. T. T. Li, M. Alemayehu, A. I. Aziziyeh, C. Pape, M.Pampillo, L.M. Postovit,G. B.Mills, A. V. Babwah, M. Bhattacharya, β-Arrestin/Ral signaling regulates lysophosphatidic acid-mediated migration and invasion of human breast tumor cells. Mol. Cancer Res. 7, 1064-1077 (2009).
42. B. Luan, J. Zhao, H. Wu, B. Duan, G. Shu, X. Wang, D. Li, W. Jia, J. Kang, G. Pei, Deficiency of a β-arrestin-2 signal complex contributes to insulin resistance. Nature 457, 1146-1149 (2009).
43. J.-M. Beaulieu, T. D. Sotnikova, S. Marion, R. J. Lefkowitz, R. R. Gainetdinov, M. G. Caron, An Akt/b-arrestin 2/PP2A signaling complex mediates dopaminergic neurotransmission and behavior. Cell 122, 261-273 (2005).
44. J.-M. Beaulieu, S. Marion, R. M. Rodriguiz, I. O. Medvedev, T. D. Sotnikova, V. Ghisi, W. C. Wetsel, R. J. Lefkowitz, R. R. Gainetdinov, M. G. Caron, A β-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132, 125-136 (2008).
45. E. R. Bychkov, V. V. Gurevich, J. N. Joyce, J. L. Benovic, E. V. Gurevich, Arrestins and two receptor kinases are upregulated in Parkinson's disease with dementia. Neurobiol. Aging 29, 379-396 (2008).
46. S. Tsutsui, D. Vergote, N. Shariat, K. Warren, S. S. Ferguson, C. Power, Glucocorticoids regulate innate immunity in a model of multiple sclerosis: Reciprocal interactions between the A1 adenosine receptor and b-arrestin-1 in monocytoid cells. FASEB J. 22, 786-796 (2008).
47. E. J. Whalen, S. Rajagopal, R. J. Lefkowitz, Therapeutic potential of β-arrestin- and G proteinbiased agonists. Trends Mol. Med. 17, 126-139 (2011).
48. W. G. Annaert, C. Esselens, V. Baert, C. Boeve, G. Snellings, P. Cupers, K. Craessaerts, B. De Strooper, Interaction with telencephalin and the amyloid precursor protein predicts a ring structure for presenilins. Neuron 32, 579-589 (2001).
49. C. Esselens, V. Oorschot, V. Baert, T. Raemaekers, K. Spittaels, L. Serneels, H. Zheng, P. Saftig, B. De Strooper, J. Klumperman, W. Annaert, Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J. Cell Biol. 166, 1041-1054 (2004).
50. L. M. Mehlmann, Y. Saeki, S. Tanaka, T. J. Brennan, A. V. Evsikov, F. L. Pendola, B. B. Knowles, J. J. Eppig, L. A. Jaffe, The Gs-linked receptor GPR3 maintains meiotic arrest in mammalian oocytes. Science 306, 1947-1950 (2004).
51. M. Morishima-Kawashima, N. Oshima, H. Ogata, H. Yamaguchi, M. Yoshimura, S. Sugihara, Y. Ihara, Effect of apolipoprotein E allele e4 on the initial phase of amyloid β-protein accumulation in the human brain. Am. J. Pathol. 157, 2093-2099 (2000).
52. R. D'Hooge, R. Lüllmann-Rauch, T. Beckers, D. Balschun, M. Schwake, K. Reiss, K. von Figura, P. Saftig, Neurocognitive and psychotiform behavioral alterations and enhanced hippocampal long-term potentiation in transgenic mice displaying neuropathological features of human amannosidosis. J. Neurosci. 25, 6539-6549 (2005).
53. H.-U. Dodt, U. Leischner, A. Schierloh, N. Jährling, C. P. Mauch, K. Deininger, J. M. Deussing, M. Eder, W. Zieglgänsberger, K. Becker, Ultramicroscopy: Three-dimensional visualization of neuronal networks in the whole mouse brain. Nat. Methods 4, 331-336 (2007).
54. K. Bossers, K. T. S. Wirz, G. F. Meerhoff, A. H. W. Essing, J. W. van Dongen, P. Houba, C. G. Kruse, J. Verhaagen, D. F. Swaab, Concerted changes in transcripts in the prefrontal cortex precede neuropathology in Alzheimer's disease. Brain 133, 3699-3723 (2010).
55. D. Trabzuni, M. Ryten, R. Walker, C. Smith, S. Imran, A. Ramasamy, M. E. Weale, J. Hardy, Quality control parameters on a large dataset of regionally dissected human control brains for whole genome expression studies. J. Neurochem. 119, 275-282 (2011).
56. R. A. Irizarry, B. Hobbs, F. Collin, Y. D. Beazer-Barclay, K. J. Antonellis, U. Scherf, T. P. Speed, Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264 (2003).